Karyopharm Therapeutics Inc. (KPTI)
KPTINASDAQ-GSBiotechnology: Pharmaceutical Preparations
$0.0340
-0.0209 (-38.07%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $907.3k
- P/E
- –
- EPS, last 4 quarters
- $-9.61
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.0401 to $10.99
- Average volume
- 7.07m
- Previous close
- $0.0549
Analysts
3 coveringHold2 buy, 1 hold, 0 sell
Targets a year out average $5.84, +17076.5% from here
Earnings
next estimate $-1.05Next report
Sep 2025
-15.8%
Dec 2025
+1.3%
Mar 2026
+14.5%
Jun 2026
-51.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $44.04m | $34.08m | $35.07m | $33.43m |
| Gross profit | $41.93m | $32.59m | $33.72m | $32.35m |
| Operating income | -$15.22m | -$17.84m | -$26.76m | -$22.53m |
| Net income | -$33.13m | -$102.20m | -$22.39m | -$67.02m |
Last four quarters: revenue $146.62m, margin -153.3%, free cash flow –
News
8 latest- Karyopharm Therapeutics Inc. to be Delisted from Nasdaq Following Chapter 11 Bankruptcy PetitionsFintel · 4 days ago
- Karyopharm Therapeutics Inc. Files for Chapter 11 Bankruptcy on November 2, 2026Fintel · 7 days ago
- Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings EstimatesZacks · Oct 30, 2026
- Karyopharm Therapeutics Inc. Extends Forbearance Period to November 1, 2026Fintel · Oct 22, 2026
- Karyopharm Submits SNDA For XPOVIO Plus Ruxolitinib In Myelofibrosis; Stock Up RTTNews · Aug 31, 2026
- Karyopharm Submits SNDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib RTTNews · Aug 31, 2026
- Active Biotech's Q2 Loss Shrinks As Dosing Begins In Myelofibrosis Trial RTTNews · Aug 20, 2026
- Karyopharm (KPTI) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 20, 2026
The company
Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S . for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO in more than 50 ex- U.S . countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts , Karyopharm has an established, efficient and scalable commercialization infrastructure to bring novel therapeutic options to patients with cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- karyopharm.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.